Kazia Therapeutics Ltd (KZIA) stock
Close on Nov 17, 2026Market cap $8.60MP/E –Yield –
Kazia Therapeutics Ltd saw revenue fall 98.2% to A$42.00K over fiscal 2025. At the latest close the market valued the company at A$12.69M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- A$12.69M
- P/E ratio
- –
- Price to sales
- 302.09
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- A$42.00K
- Net income
- -A$20.70M
- EPS, diluted
- -0.04 AUD
Trading
- Previous close
- $5.60
- Open
- $5.60
- Day's range
- $5.20 – $5.85
- Volume
- 650,852
- Average volume (20 days)
- 261,170
- RSI (14 days)
- 23.7
- Volatility (1 year)
- 128.3%
- Relative volume
- 2.49×
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | KZIA | S&P 500 | Difference | KZIA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.8% | -4.0% | −22.7 pts | ||
| 3 months | -60.8% | -5.0% | −55.9 pts | ||
| Year to date | -22.9% | +8.2% | −31.2 pts | ||
| 1 year | -12.7% | +11.2% | −23.9 pts | ||
| 3 years | -87.1% | +68.5% | −155.6 pts | -49.4% | +19.0% |
| 5 years | -99.1% | +67.3% | −166.4 pts | -60.8% | +10.8% |
| 10 years | -98.4% | +291.6% | −390.1 pts | -34.0% | +14.6% |
Eleven years at a glance
Fiscal years 2015 to 2025, AUD
Revenue
Net income
EPS, diluted
Free cash flow
Press releases
Releases Kazia Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Kazia Therapeutics
Pharmaceutical Preparations
Kazia Therapeutics Limited is a clinical-stage biotechnology company that focuses on the development of anti-cancer drug candidates. The company directs its operations toward targeted cancer therapies, concentrating on core pipeline assets including paxalisib, an investigational treatment for brain cancers and solid tumors, and EVT801, a selective VEGFR-3 inhibitor, alongside research associated with cantrixil. Kazia commercializes and advances its pipeline by partnering with international pharmaceutical and biotechnology enterprises through commercial and territory-based licensing agreements.
Company profile, executives and historyKazia Therapeutics stock: common questions
What is Kazia Therapeutics's stock price?
KZIA closed at $5.31 on Nov 17, 2026, down 5.18% on the day.
What is Kazia Therapeutics's market cap?
Kazia Therapeutics was worth $8.60M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is KZIA's P/E ratio?
Kazia Therapeutics lost money over fiscal 2025 (diluted EPS -0.04 AUD), so it has no meaningful P/E ratio.
How much revenue does Kazia Therapeutics make?
Kazia Therapeutics reported revenue of A$42.00K for fiscal 2025, down 98.2% from a year earlier.
Does Kazia Therapeutics pay a dividend?
No. Kazia Therapeutics has not paid a cash dividend over the last twelve months.
How has KZIA stock performed over the past year?
Including dividends, KZIA returned -12.7% over the past year, against +11.2% for the S&P 500.
Who are Kazia Therapeutics's competitors?
Companies most similar to Kazia Therapeutics by business, industry and size include CNBX, NTHI, LSTA, KPRX, IXHL.
See a number that looks wrong?